Head to Head Review: United Therapeutics (NASDAQ:UTHR) vs. Small Pharma (OTCMKTS:DMTTF)

Small Pharma (OTCMKTS:DMTTF) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Small Pharma and United Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Small Pharma	N/A	N/A	N/A
United Therapeutics	41.56%	20.18%	17.98%

Insider & Institutional Ownership

94.1% of United Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Small Pharma and United Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Small Pharma	0	0	0	0	0.00
United Therapeutics	0	2	11	0	2.85

United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 24.65%. Given United Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Small Pharma.

Earnings & Valuation

This table compares Small Pharma and United Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Small Pharma	N/A	N/A	N/A	N/A	N/A
United Therapeutics	$3.18 billion	6.98	$1.33 billion	$27.95	18.54

United Therapeutics has higher revenue and earnings than Small Pharma.

Summary

United Therapeutics beats Small Pharma on 9 of the 9 factors compared between the two stocks.

About Small Pharma

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.